Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a hard cycling sprint change a Heart-Calming peptide?

NCT ID NCT07819422

Knowledge-focused Sponsor: Firat University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 15, 2026 · Last updated Sep 16, 2026 · Updated 1 time

Summary

Researchers are studying how two different cycling workouts affect catestatin, a peptide that helps control the body's stress response and heart function. Twenty healthy but sedentary young men complete either a high-intensity interval session or a moderate continuous session on a stationary bike. The team measures catestatin and a related protein in blood samples before, right after, and during an hour of recovery, while tracking heart rate to see how quickly it returns to normal.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
high-intensity interval exercise and moderate-intensity continuous exercise on a cycle ergometer
What this could lead to
If catestatin tracks with faster heart rate recovery, it could become a measurable marker for how well the body's nervous system handles exercise stress. That may one day help tailor exercise prescriptions.
What could go wrong
This is a small, single-site study of 20 healthy young men, so its findings may not apply to women, older adults, or people with health conditions. It measures short-term blood and heart rate changes, not long-term health outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

20 people

The number who actually took part.

Started

Oct 2025

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 25 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy male individuals aged 18-25 years * Body mass index (BMI) between 18.0 and 25.0 kg/m² * Sedentary lifestyle (no regular exercise engagement within the last 3 months; \<90 min/week moderate-intensity or \<60 min/week vigorous-intensity exercise) * Normal resting blood pressure (\<140/90 mmHg) * Fasting plasma glucose between 60 and 100 mg/dL * Normal resting electrocardiogram (ECG) and pulmonary function tests (FEV1/FVC \>80%) * Signed written informed consent Exclusion Criteria: * Regular smoking or alcohol consumption * Any current or regular medication use * History or clinical signs of cardiovascular, respiratory, metabolic, or renal diseases * Symptoms suggestive of cardiopulmonary/metabolic disease (chest pain, shortness of breath, dizziness, syncope, ankle edema, palpitations, intermittent claudication) * Presence of known cardiovascular risk factors * Iron deficiency / anemia * Musculoskeletal limitations or contraindications to maximal cycle ergometer testing

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autonomic nervous system regulation are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Autonomic nervous system regulation Exercise physiology Healthy volunteers

Contacts and locations

Locations

  • Firat University Medical Faculty, Department of Physiology

    Elâzığ, Elâzığ, 23119, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.